Following the science to change lives.

89bio addresses urgent needs in liver and metabolic disorders.

About 89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Pipeline

INDICATION PRODUCT CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3
NASH BIO89-100
NASH and related liver
and metabolic disorders
Undisclosed

About BIO89-100

BIO89-100 is a novel long-acting glycopegylated FGF21 analogue for the treatment of NASH. It was engineered using a proprietary glycopegylation technology to prolong the biological activity of native FGF21. In preclinical studies BIO89-100 demonstrated a long half-life, potentially enabling extended-interval dosing. BIO89-100 also showed significant improvements in liver fat, hepatic injury and fibrosis and metabolic biomarkers including triglycerides, cholesterol, body weight, and glycemic control parameters.

About FGF21

FGF21 is an endogenous metabolic hormone that serves as a key regulator of carbohydrate and lipids metabolism. FGF21 acts on multiple sites to reduce liver fat, increase insulin sensitivity and suppress lipolysis. As such FGF21 has the potential to target several pathways leading to NASH progression such as steatosis, inflammation, and fibrosis. In studies, FGF21 has demonstrated a beneficial effect on a broad range of metabolic biomarkers as well as improvement in liver fat, hepatic injury and fibrosis biomarkers, suggesting an independent anti-fibrotic effect.

About NASH

NASH is a complex metabolic disorder. It causes fat buildup in the liver, as well as inflammation and eventually fibrosis, and it can worsen to cirrhosis and liver failure. NASH affects more than 16 million adults in the US. The exact cause of NASH is unknown, but it is commonly found in people with obesity and type 2 diabetes. It is predicted that by 2020, NASH will surpass hepatitis C as the leading cause of liver transplant, and by 2030 its prevalence will increase by 63%. There are no approved treatments for NASH.

News

11 /15 / 2018Press Release
89bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Investment round led by company founders, OrbiMed Israel and OrbiMed US, and Longitude Capital, with participation by RA Capital Management and Pontifax

Leadership

Rohan Palekar
CEO
Dr. Michal Ayalon
Head of R&D
Ram Waisbourd
Chief Operating Officer & Chief Business Officer

Board of Directors

Anat Naschitz
Managing Director, OrbiMed
Dr. Gregory Grunberg
Managing Director, Longitude Capital
Derek DiRocco, PhD
Principal, RA Capital Management
Tomer Kariv
Co-founder and CEO, Pontifax
Dr. Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Rohan Palekar
CEO, 89bio

Investors